Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical condition characterized by asthma, aspirin /NSAIDs hypersensitivity and chronic rhinosinusitis with nasal polyps (CRSwNP). Challenging part of the treatment comes from intractable nasal polyps and/or chronic sinusitis requiring recurrent multiple nasal surgeries as well as severe asthma. Current developments provide two specific treatments for N-ERD. Aspirin desensitization (AD), was discovered in 1982 in Scripps Clinic. Subsequent studies showed delayed occurrence of nasal polyps and better asthma outcomes. Recently, biologic therapies have also emerged as a promising therapeutic option in N-ERD. In this sense; anti-IgE (omalizumab), Anti-IL-5 therapies (mepolizumab, reslizumab, benralizumab) and anti- IL-4 therapy (dupilumab) were studied. Each treatment ways seem to have both advantages and disadvantages. Therefore, decision about which treatment to select in N-ERD seems to be challenging. To address this issue, in this task force we aimed to see physician’s attitude, experience and need about use of AD or biologicals (if possible by comparing Europe and US) to prepare a practise parameter based on evidence based recommendations for use/selection of either treatments in patients with N-ERD.

WG Biologicals (Basic & Clinical Immunology Section)

Chair: Gülfem Elif Çelik

Secretary: Joanna Makowska